| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -0.4 | -0.2 |
| Net income | -0.4 | -0.2 |
| EPS (diluted, $ a share) | $-0.01 | $-0.01 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
Source
Read the filing ↗
10-Q filed with the SEC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
BioKey (Cayman), Inc.: key numbers
- Shares outstanding
- 30MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.